<DOC>
	<DOCNO>NCT02441465</DOCNO>
	<brief_summary>This study characterize pharmacokinetics ( PK ) single intravenous ( IV ) infusion ^14 C-labeled vemurafenib administer shortly oral dose vemurafenib follow multiple oral dos vemurafenib twice daily ( BID ) steady state well estimate absolute bioavailability multiple oral dos vemurafenib BID steady state participant BRAF^V600 mutation-positive malignancy .</brief_summary>
	<brief_title>Bioavailability Study Vemurafenib Patients With BRAF^V600 Mutation-Positive Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Participants either unresectable metastatic melanoma positive BRAF^V600 mutation malignant tumor type harbor V600activating mutation BRAF , vemurafenib accept standard care generally accept standard care Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy &gt; = 12 week Full recovery effect major surgery significant traumatic injury within 14 day first dose study drug Adequate hematologic end organ function define laboratory result obtain within 2 week prior administration study drug Day 1 Female patient childbearing potential male patient partner childbearing potential must agree use two effective method contraception study least 6 month completion study drug Negative serum pregnancy test result within 7 day prior Day 1 woman childbearing potential Absence psychological , familial , sociological condition , geographical constraint could potentially hamper compliance study protocol followup schedule Prior anticancer therapy administration study drug Day 1 Invasive malignancy BRAF mutant melanoma qualify malignant tumor BRAF^V600 mutation within past 5 year History clinically significant cardiac pulmonary dysfunction Active central nervous system lesion Current , severe , uncontrolled systemic disease Inability unwillingness swallow tablet History malabsorption , stomach intestinal surgery/resection , condition would potentially alter absorption and/or excretion orally administer drug History clinically significant liver disease Active autoimmune disease Uncontrolled ascites require weekly largevolume paracentesis 3 consecutive week prior enrollment Pregnancy , lactation , breastfeed Need take concomitant medication , dietary supplement , food prohibit study Known allergy sensitivity component vemurafenib formulation Active , uncontrolled chronic infection require chronic suppressive antibiotic Use prescription medications/products , know strong cytochrome P450 ( CYP ) 3A4 inhibitor inducer within 2 week prior Day 1 Participation investigational drug study receipt investigational study drug occur within 30 day prior Day 1 within 5 time elimination halflife respective drug ( whichever short ) Participation trial involve administration ^14 Cradiolabeled compound ( ) within 6 month prior Day 1 Poor peripheral venous access Any acute chronic condition , opinion investigator , could limit patient 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>